The Confluence of Innovation in Therapeutics and Regulation: Recent CMC Considerations
Authors:
- Lucas GutierrezLGLucas Gutierrez
- Nina S. CauchonNCNina S. Cauchon
- Twinkle R. ChristianTCTwinkle R. Christian
- Michael J. GiffinMGMichael J. Giffin
- Michael J. AbernathyMAMichael J. Abernathy
Open Access
- 1 December 2020
- journal article
- review article
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 109 (12) , 3524-3534
Abstract
No abstract availableKeywords
Funding Information
- Amgen
This publication has 50 references indexed in Scilit:
- Allogeneic tumor cell vaccinesHuman Vaccines & Immunotherapeutics, 2013
- ZFN, TALEN, and CRISPR/Cas-based methods for genome engineeringTrends in Biotechnology, 2013
- Quantitative and sensitive detection of the SARS-CoV spike protein using bispecific monoclonal antibody-based enzyme-linked immunoassayJournal of Virological Methods, 2013
- Designed Ankyrin Repeat Proteins (DARPins)2012
- Influence of particle size on regional lung deposition – What evidence is there?International Journal of Pharmaceutics, 2011
- Selective Expansion of Chimeric Antigen Receptor-targeted T-cells with Potent Effector Function using Interleukin-4Journal of Biological Chemistry, 2010
- The safety and side effects of monoclonal antibodiesNature Reviews Drug Discovery, 2010
- DARPins: A new generation of protein therapeuticsDrug Discovery Today, 2008
- Subcutaneous drug delivery and the role of the lymphaticsDrug Discovery Today: Technologies, 2005
- Challenges in the development of high protein concentration formulationsJournal of Pharmaceutical Sciences, 2004